Search Results - "Kumada, H."

Project for the development of the linac based NCT facility in University of Tsukuba by Kumada, H., Matsumura, A., Sakurai, H., Sakae, T., Yoshioka, M., Kobayashi, H., Matsumoto, H., Kiyanagi, Y., Shibata, T., Nakashima, H.

“…A project team headed by University of Tsukuba launched the development of a new accelerator based BNCT facility. In the project, we have adopted…”
Get full text

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C by Hayashi, N., Okanoue, T., Tsubouchi, H., Toyota, J., Chayama, K., Kumada, H.

“…The aims of this phase III study were to assess the efficacy and safety of telaprevir in combination with peginterferon alfa‐2b (PEG‐IFN) and ribavirin (RBV)…”
Get full text

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) by Finn, R.S., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B-Y., Ren, Z., Cheng, A-L., Galle, P.R., Kaneko, S., Kumada, H., Wang, A., Mody, K., Dubrovsky, L., Siegel, A.B., Llovet, J.

Get full text

Investigation of the neutron spectrum measurement method for dose evaluation in boron neutron capture therapy by Onishi, T., Kumada, H., Takada, K., Naito, F., Kurihara, T., Sakae, T.

“…In boron neutron capture therapy, it is important to evaluate the dose administered to a patient's body outside the tumour area. The exposure dose is evaluated…”
Get full text

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy by Hayes, C Nelson, Kobayashi, Mariko, Akuta, Norio, Suzuki, Fumitaka, Kumada, Hiromitsu, Abe, Hiromi, Miki, Daiki, Imamura, Michio, Ochi, Hidenori, Kamatani, Naoyuki, Nakamura, Yusuke, Chayama, Kazuaki

“…A number of recent studies have shown that human polymorphisms near the IL28B type III interferon (IFNλ) gene influence the response to peg-interferon plus…”
Get more information

Clinical results of boron neutron capture therapy (BNCT) for glioblastoma by Kageji, T., Mizobuchi, Y., Nagahiro, S., Nakagawa, Y., Kumada, H.

“…The purpose of this study was to evaluate the clinical outcome of BSH-based intra-operative BNCT (IO-BNCT) and BSH and BPA-based non-operative BNCT (NO-BNCT)…”
Get full text

Fatal carotid blowout syndrome after BNCT for head and neck cancers by Aihara, T., Hiratsuka, J., Ishikawa, H., Kumada, H., Ohnishi, K., Kamitani, N., Suzuki, M., Sakurai, H., Harada, T.

“…Boron neutron capture therapy (BNCT) is high linear energy transfer (LET) radiation and tumor-selective radiation that does not cause serious damage to the…”
Get full text

Study of charged particle activation analysis (II): Determination of boron concentration in human blood samples by Ikebe, Y., Oshima, M., Bamba, S., Asai, M., Tsukada, K., Sato, T.K., Toyoshima, A., Bi, C., Seto, H., Amano, H., Kumada, H., Morimoto, T.

“…Boron Neutron Capture Therapy (BNCT) is a radiotherapy for the treatment of intractable cancer. In BNCT precise determination of 10B concentration in whole…”
Get full text

Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in Japan by Umemura, Takeji, Tanaka, Eiji, Kiyosawa, Kendo, Kumada, Hiromitsu

“…Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection was found in 23 (4%) of 552 newly hepatitis B surface antigen-positive patients in…”
Get full text

Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study by Ikeda, K., Kobayashi, M., Someya, T., Saitoh, S., Hosaka, T., Akuta, N., Suzuki, F., Suzuki, Y., Arase, Y., Kumada, H.

“…An impact of serum hepatitis B virus (HBV) DNA on hepatocarcinogenesis has not been investigated in a cohort of patients with non‐B, non‐C cirrhosis…”
Get full text

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection by Yamada, I., Suzuki, F., Kamiya, N., Aoki, K., Sakurai, Y., Kano, M., Matsui, H., Kumada, H.

“…Background: Telaprevir in combination with peginterferon and ribavirin is a promising advancement in chronic hepatitis C treatment. However, the safety,…”
Get full text

Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients by Hara, T., Suzuki, F., Kawamura, Y., Sezaki, H., Hosaka, T., Akuta, N., Kobayashi, M., Suzuki, Y., Saitoh, S., Arase, Y., Ikeda, K., Kobayashi, M., Watahiki, S., Mineta, R., Kumada, H.

“…Summary Entecavir (ETV) is reported to result in suppression of hepatitis B virus DNA (HBV DNA) replication with minimal drug resistance. However, information…”
Get full text

Correlation between radiation dose and histopathological findings in patients with gliblastoma treated with boron neutron capture therapy (BNCT) by Kageji, T., Mizobuchi, Y., Nagahiro, S., Nakagawa, Y., Kumada, H.

“…The purpose of this study was to clarify the correlation between the radiation dose and histopathological findings in patients with glioblastoma multiforme…”
Get full text

Study on magnetite nanoparticles synthesized by chemical method by Pei, Wenli, Kumada, H., Natusme, T., Saito, H., Ishio, S.

“…Magnetite nanoparticles with controlled size were synthesized by chemical method. Higher deposition temperature and a rapid-raising temperature procedure are…”
Get full text

CERTAIN-1: efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis by Chayama, K, Suzuki, F, Karino, Y, Kawakami, Y, Sato, K, Atarashi, T, Naganuma, A, Watanabe, T, Eguchi, Y, Yoshiji, H, Seike, M, Takei, Y, Kato, K, Alves, K, Burroughs, M, Redman, R, Pugatch, D.L, Pilot-Matias, T, Xie, W, Kumada, H

Get full text

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection with and without cirrhosis by Chayama, K, Suzuki, F, Sato, K, Atarashi, T, Watanabe, T, Toyoda, H, Atsukawa, M, Naganuma, A, Notsumata, K, Osaki, Y, Nakamuta, M, Takaguchi, K, Saito, S, Kato, K, Pugatch, D.L, Burroughs, M, Redman, R, Alves, K, Pilot-Matias, T, Fu, B, Kumada, H

Get full text

Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT) by Kageji, T., Mizobuchi, Y., Nagahiro, S., Nakagawa, Y., Kumada, H.

“…The purpose of this study was to compare the radiation dose between long-survivors and non-long-survivors in patients with glioblatoma (GBM) treated with boron…”
Get full text

P572 INSULIN USE IS RELATED TO THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA AT YOUNGER AGE WITH NON-VIRAL ETIOLOGY by Tateishi, R, Okanoue, T, Okita, K, Kiyosawa, K, Omata, M, Kumada, H, Hayashi, N, Koike, K

Get full text

G13 : Ombitasvir/paritaprevir/ritonavir for treatment of HCV genotype 1b in Japanese patients with or without cirrhosis: Results from gift-I by Chayama, K, Suzuki, F, Ikeda, K, Toyoda, H, Sato, K, Karino, Y, Matsuzaki, Y, Kioka, K, Pilot-Matias, T, Setze, C, Zhang, X, Badri, P, Yanke, T, Matsuda, T, Vilchez, R.A, Rodrigues-Jr, L, Kumada, H

Get full text

825 ANALYSIS OF THE OPTIMAL TVR DOSE PER WEIGHT JUDGING FROM ANEMIA DURING PEG-IFN/RBV/TVR COMBINATION THERAPY by Karino, Y, Ozeki, I, Hige, S, Toyota, J, Imamura, M, Tsuge, M, Chayama, K, Akuta, N, Suzuki, F, Kumada, H

Get full text